4.5 Article

Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma

期刊

BIOCHIMIE
卷 202, 期 -, 页码 180-189

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biochi.2022.07.016

关键词

Hepatocellular carcinoma (HCC); Sorafenib resistance; Lysophosphatidic acid receptor 6 (LPAR6); Energy metabolism; Oxidative phosphorylation (OXPHOS)

资金

  1. Agenzia Regionale Strategica per la Salute ed il Sociale -ARESS

向作者/读者索取更多资源

Hepatocellular carcinoma (HCC) is a highly threatening tumor, and the current pharmacological treatments for HCC rely on protein kinase inhibitors. However, these approaches often result in side effects and drug resistance. This study reveals that LPAR6-mediated metabolic mechanism contributes to sorafenib resistance in HCC and proposes a pharmacological approach to overcome it.
Hepatocellular carcinoma (HCC) is one of the most threatening tumours in the world today. Pharma-cological treatments for HCC mainly rely on protein kinase inhibitors, such as sorafenib and regorafenib. Even so, these approaches exhibit side effects and acquired drug resistance, which is an obstacle to HCC treatment. We have previously shown that selective lysophosphatidic acid receptor 6 (LPAR6) chemical antagonists inhibit HCC growth. Here, we investigated whether LPAR6 mediates resistance to sorafenib by affecting energy metabolism in HCC. To uncover the role of LPAR6 in drug resistance and cancer energy metabolism, we used a gain-of-function and loss-of-function approach in 2D tissue and 3D spheroids. LPAR6 was ectopically expressed in HLE cells (HLE-LPAR6) and knocked down in HepG2 (HepG2 LPAR6-shRNA). Measurements of oxygen consumption and lactate and pyruvate production were performed to assess the energy metabolism response of HCC cells to sorafenib treatment. We found that LPAR6 mediates the resistance of HCC cells to sorafenib by promoting lactic acid fermentation at the expense of oxidative phosphorylation (OXPHOS) and that the selective LPAR6 antagonist 9-xanthenyl acetate (XAA) can effectively overcome this resistance. Our study shows for the first time that an LPAR6-mediated metabolic mechanism supports sorafenib resistance in HCC and proposes a pharma-cological approach to overcome it.(c) 2022 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据